Heart and Vascular Research

Research at MetroHealth

Research is a major part of both of the fellowship programs offered through the Cardiovascular Department at MetroHealth. Not surprisingly then, MetroHealth is home to a world-class cardiovascular research facility, and our clinicians perform groundbreaking research on a regular basis. Our investment in a research facility, and our staff's commitment to research, ensures that our fellows can learn more about how research studies are conducted and how study results can improve clinical care delivered to patients.

Read more about our facility and our programs on this page. We encourage all qualified students to enroll in our program and be a part of the excellent work we do here.

About the Heart and Vascular Research Center

The Heart and Vascular Research Center (HVRC) was established to promote excellence in cardiovascular research. The HVRC's multidisciplinary approach utilizes the extraordinary range of outstanding investigative talents available at MetroHealth. HVRC faculty hold appointments in the Departments of Biomedical Engineering, Physiology and Biophysics, Developmental Biology and Neuroscience at Case Western Reserve University.

Our aim is to understand the mechanisms, diagnosis and treatment of cardiovascular disease. We reach that goal by applying state-of-the-art engineering, molecular, cellular, organ and clinical investigative approaches to specific cardiac disease states. This program features internationally recognized scientific programs in gene and cell therapies for cardiovascular disease.

Our work allows us to bring novel medications and cardiac care techniques to MetroHealth patients. In addition, the HVRC provides an outstanding training environment for the next generation of cardiovascular investigators.

We perform two levels of research in the center.

Basic science research, which focuses on molecular, ion channel and cellular mechanisms of cardiac physiology. Novel techniques include optical mapping, as well as confocal and fluorescent microscopy. The expression of genes that regulate cardiac electrophysiology and hemodynamics are explored using transgenic and mutagenesis.  Induced pluripotent stem cells (iPS) to study genetic and acquired forms of arrhythmias.  Stem cell biology to study potential regeneration of the heart.  Animal models of heart failure, cardiac remodeling and re-entrant arrhythmias are other ongoing research initiatives.

Clinical research, which includes:

  • Heart failure trials, T-wave alternans, heart rate variability, and other electrocardiographic indices for the prediction of sudden death
  • New techniques of catheter ablation of atrial fibrillation
  • Intravascular ultrasound and fractional flow reserve in acute coronary syndromes
  • Minimally invasive robot-assisted cardiac surgical procedures
  • Assessment of novel echocardiographic indices of various disease states
  • Innovations with cardiac magnetic resonance imaging
  • Diagnosis of acute coronary syndromes using biomarkers

Clinical Trials Unit

Within the Heart and Vascular Research Center lies the Clinical Trials Unit. The research studies underway are collaborative in nature. They promote interaction between clinicians, clinical investigators, biologists and biomedical engineers. This collaboration ensures that new, cutting-edge diagnostic techniques, treatments and medical discoveries transition efficiently and effectively from the laboratory bench to the bedside. That provides patients with access to procedures and therapies not widely available.

Recent Fellow Publications

(see complete list)

  1. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure. Ghosh RK, Ghosh GC, Gupta M, Bandyopadhyay D, Fonarow GC, Aneja A. 2019 Sep;19.
  1. Quantification of image texture in X-ray phase-contrast-enhanced projection images of in vivo mouse lungs observed at varied inflation pressures. Brooks FJ, Gunsten SP, Vasireddi SK, Brody SL, Anastasio MA. Physiol Rep.2019 Aug;7(16):e14208.
  1. Serum Bilirubin and Coronary Artery Disease: Intricate Relationship, Pathophysiology and Recent Evidence. Vardhmaan Jain MBBS, Raktim K Ghosh MD, Dhrubajyoti Bandyopadhyay MD, Meera Kondapaneni MD, Wilbert Aronow MD, Carl J Lavie MD Current Problems in Cardiology 2019 June 22, : 100431
  1. Gender Related Differences in the Diagnosis and Treatment of Atrioventricular Nodal Reentrant Tachycardia. Musa TA , Darrat Y, Etaee F, Butt MU , Czarapata M, McMullen C, Mattingly L Daoud A , Coy K , Ogunbayo G , Delisle B , Elayi CS Pacing Clin Electrophysiol. 2019 Jul;42(7):937-941. doi: 10.1111/pace.13735
  1. Fluctuations in premature ventricular contraction burden can affect medical assessment and management. Mullis AH, Ayoub K, Shah J , Butt MU, Suffredini J, Czarapata M, Delisle B, Ogunbayo GO DarratY, Elayi CS. Heart Rhythm. 2019 Apr 18. pii: S1547-5271(19)30362-5. doi: 10.1016/j.hrthm.2019.04.033\
  1. Retropharyngeal, Mediastinal, Retroperitoneal Edema: A Rare Presentation of Angiotensin Converting Enzyme Inhibitor (ACEI) Induced Angioedema. Butt MU, , J Ahmad , Elayi SC. JOJ Internal Medicine. 2019 volume1, Issue 1
  1. Azithromycin-Induced Thrombocytopenia: A Rare Etiology of Drug-Induced Immune Thrombocytopenia Shock. Butt MU, J Ahmad , Elayi SC. Case Reports in Medicine, vol. 2019, Article ID 6109831, 3 pages, 2019.
  1. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.Dhorepatil A, Ball S, Ghosh RK, Kondapaneni M, Lavie CJ. Am J Med. 2019 Mar;132(3):312-324. doi: 10.1016/j.amjmed.2018.10.013. Epub 2018 Oct 25. PMID: 30832770
  2. Does Insurance Effect the Outcome in Patients With Acute Coronary Syndrome?: An Insight from the Most Recent National Inpatient Sample. Curr Probl Cardiol. Chakraborty S, Bandyopadhyay D, Amgai B, Sidhu JS, Paudel R, Koirala S, Hajra A, Ghosh RK, Lavie CJ. 2019 Feb 28. pii: S0146-2806(19)30020-9. doi: 10.1016/j.cpcardiol.2019.02.003. PMID: 30917889
  1. Bleeding Risk Scores in Atrial Fibrillation: Helpful or Harmful?Edmiston MK, Lewis WR. J Am Heart Assoc. 2018 Sep 18;7(18):e010582.
  1. RAID Trial Investigators. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. Zareba W, Daubert JP, Beck CA, Huang DT, Alexis JD, Brown MW, Pyykkonen K, McNitt S, Oakes D, Feng C, Aktas MK, Ayala-Parades F, Baranchuk A, Dubuc M, Haigney M, Mazur A, McPherson CA, Mitchell LB, Natale A, Piccini JP, Raitt M, Rashtian MY, Schuger C, Winters S, Worley SJ, Ziv O, Moss AJ. J Am Coll Cardiol. 2018 Aug 7;72(6):636-645.
  2. Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: A Transatlantic Experience. Orgeron GM1, Bhonsale A1, Migliore F2, James CA1, Tichnell C1, Murray B1, Bertaglia E2, Cadrin-Tourigny J1, De Franceschi P2, Crosson J1, Tandri H1, Corrado D2, Calkins H1. J Am Heart Assoc. 2018 Nov 6;7(21):e008782. doi: 10.1161/JAHA.118.008782.
  3. Impact of Exercise Restriction on Arrhythmic Risk Among Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. Wang W1, Orgeron G2, Tichnell C2, Murray B2, Crosson J2, Monfredi O2, Cadrin-Tourigny J2, Tandri H2, Calkins H2, James CA2. J Am Heart Assoc. 2018 Jun 16;7(12). pii: e008843. doi: 10.1161/JAHA.118.008843.
  4. Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Orgeron GM1, Te Riele A1, Tichnell C1, Wang W1, Murray B1, Bhonsale A1, Judge DP1, Kamel IR1, Zimmerman SL1, Tandri H1, Calkins H1, James CA2. Circ Arrhythm Electrophysiol. 2018 Feb;11(2):e005593. doi: 10.1161/CIRCEP.117.005593. Epub 2018 Feb 16.
  5. Novel imaging modalities to predict the development of atrial fibrillation post stroke. Faisaluddin M, Bandyopadhyay D, Hajra A, Beydoun H, Ghosh RK, Herzog E. Int J Cardiol Heart Vasc. 2018 Dec 13;22:46-47.[PMID: 30581981]
  6. Significance of Pulmonary Hypertension in Hypertrophic Cardiomyopathy. Mitra A, Ghosh RK, Bandyopadhyay D, Ghosh GC, Kalra A, Lavie CJ.. Curr Probl Cardiol. 2018 Oct 17. pii: S0146-2806(18)30157-9. doi: 10.1016/j.cpcardiol.2018.10.002. [Epub ahead of print] Review. [PMID: 30497690]
  7. An intriguing relation between atrial fibrillation and contrast-induced nephropathy. Ashish K, Bandyopadhyay D, Ghosh RK, Tan JL, Bose S. Int J Cardiol Heart Vasc. 2018 Oct 24;21:78-79. doi: 10.1016/j.ijcha.2018.10.005. [PMID: 30377653]
  8. Effectiveness and Safety of Inclisiran, a Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9. Ghosh GC, Bandyopadhyay D, Ghosh Rk, Mondal S, Herzog E. Am J Cardiol. 2018 Jul 3. pii: S0002-9149(18)31315-8. doi: 10.1016. [PMID: 30075894]
  9. SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality? Chatterjee S, Bandyopadhyay D, Ghosh RK, Majumdar U, Aneja A, Lavie C, Deedwania P. Curr Probl Cardiol. 2018 Jul 6. pii: S0146-2806(18)30094-X. doi: 10.1016/j.cpcardiol.2018.06.004. [PMID: 30195639]
  10. Predicting outcomes in patients with asymptomatic moderate to severe aortic stenosis.Bahler RC, Riem H, Rovner A, Finkelhor R, Thomas CL, Dawson NV. Am J Cardiology 2018;122:851-858
  11. Gender Related Differences in the Diagnosis and Treatment of Atrioventricular Nodal Reentrant Tachycardia. Musa TA , Butt MU , Coy K , Etaee F , Czarapata M , McMullen C, Daoud A , Mattingly L , Ogunbayo G , Darrat Y, Elayi CS 5 Nov 2018 Circulation. 2018;138:A10869
  12. When a Pseudo-Infarct Electrocardiogram (ECG) Pattern in a Posterior Accessory (Wolff-Parkinson-White) Pathway Masks a True Inferior InfarctButt MU, Patel R, Darrat YH, Morales GX, Elayi CS.. Am J Case Rep. 2018 July 13;19:685-688. doi: 10.12659/AJCR.909189
Disclaimer: PubMed, a service of the U.S. National Library of Medicine, is a third-party website with no affiliation with The MetroHealth System.